How smaller, smarter deals will help life sciences shape the future with confidence

Join our panel of industry leaders as we explore the findings from our 13th annual EY M&A Firepower report, “How will smaller, smarter deals help life sciences companies shape the future with confidence?”

As our report will tell you, the industry has shifted from large deals to smaller, more agile ones, with M&A investment totaling $130b in 2024, a 41% decrease from $222b in 2023. While the value dropped, deal volume remained stable (e.g., biopharma deals are +17% vs. 2023), as companies focused on earlier-stage opportunities with lower price tags.

In this webcast industry leaders will explore:

• Why dealmaking will be critical to growth in life sciences.
• Why therapeutic areas are important key priorities in dealmaking.
• Artificial intelligence (AI) startups and China biotech present accelerated growth opportunities beyond traditional areas.
• Effective dealmaking requires end-to-end execution, centered on culture and change experience, to achieve strong ROI.

Speakers:

• Subin Baral, EY Global Life Sciences Deals Leader
• Heather Meade, Principal, Washington Council EY (WCEY), Ernst & Young LLP
• Nauman Shah, Global Head, Innovative Medicine Business Development, Johnson & Johnson
• Arda Ural, Americas Industry Markets Leader, EY Health Sciences and Wellness